Janux Therapeutics, Inc.

NasdaqGM:JANX Aktierapport

Börsvärde: US$878.2m

Janux Therapeutics Framtida tillväxt

Future kriterier kontrolleras 2/6

Janux Therapeutics s intäkter förväntas minska med 19.3% per år medan dess årliga intäkter förväntas växa med 45.1% per år. EPS förväntas falla med 15% per år. Avkastningen på eget kapital förväntas bli -18.1% om 3 år.

Viktig information

-19.3%

Tillväxttakt i vinsten

-15.05%

Tillväxttakt för EPS

Biotechs vinsttillväxt25.4%
Intäkternas tillväxttakt45.1%
Framtida avkastning på eget kapital-18.05%
Bevakning av analytiker

Good

Senast uppdaterad13 May 2026

Senaste uppdateringarna om framtida tillväxt

Analysartikel • May 11

Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Janux Therapeutics, Inc. ( NASDAQ:JANX ) came out with its quarterly results last week, and we wanted to see how the...

Recent updates

Analysartikel • May 13

Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts

Celebrations may be in order for Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders, with the analysts delivering a...
Analysartikel • May 11

Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Janux Therapeutics, Inc. ( NASDAQ:JANX ) came out with its quarterly results last week, and we wanted to see how the...
Seeking Alpha • May 04

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Summary Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation. Despite early-stage pipeline risks and near-term volatility, JANX’s cash position and platform progress justify a high-risk, long-term investment thesis. Read the full article on Seeking Alpha
Analysartikel • Oct 08

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysartikel • Apr 23

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Dec 03

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Summary Janux Therapeutics' TRACTr platform shows promise with encouraging early data, but the high valuation for a phase 1 company makes it a risky investment. The PSMA-targeted JANX007 has shown significant PSA reductions and partial tumor responses, but long-term efficacy and safety remain uncertain. JANX has a strong cash position, reducing immediate financial risks, but the market's high expectations could lead to severe valuation drops if data disappoints. Despite potential buyout rumors, the unproven nature of JANX's technology and the high market cap lead me to maintain a “Strong Sell” rating. Read the full article on Seeking Alpha
Analysartikel • Oct 01

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 01

Janux Therapeutics: Buoyed By Buyout Speculation

Summary Today, we take another look at clinical stage biotech concern Janux Therapeutics, whose stock has soared in 2024. The shares have been buoyed throughout most of 2024 by a bevy of buyout speculation and some promising early-stage trial data. The company has a robust balance sheet and is targeting some potentially large markets. However, the company's pipeline is early-stage and there was some significant insider selling in the stock in early June at near all-time highs. Can the rally in Janux Therapeutics continue? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Analysartikel • Jul 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 11

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Summary Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes. I recommend a cautious 'Buy' for JANX, highlighting its speculative nature, potential risks in drug development, and competition in the mCRPC market. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Summary Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032. Positive preliminary data also observed for the other phase 1a study using JANX008 for the treatment of patients with EGFR expressing solid tumors. Read the full article on Seeking Alpha
Analysartikel • Feb 24

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysartikel • Dec 29

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Key Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity...
Analysartikel • Nov 04

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysartikel • Jul 20

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysartikel • May 23

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Insights The projected fair value for Janux Therapeutics is US$15.07 based on 2 Stage Free Cash Flow to Equity...
Analysartikel • Feb 09

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • Oct 19

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 09

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics press release (NASDAQ:JANX): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022
Analysartikel • Jun 05

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysartikel • Feb 19

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysartikel • Nov 03

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Prognoser för vinst- och omsättningstillväxt

NasdaqGM:JANX - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202814-236-267-19913
12/31/20277-182-225-14214
12/31/202631-109-144-8513
3/31/202614-114-78-78N/A
12/31/202510-114-83-82N/A
9/30/202510-102-71-70N/A
6/30/20250-106-61-60N/A
3/31/20259-78-47-46N/A
12/31/202411-69-44-44N/A
9/30/202413-61-38-37N/A
6/30/202415-44-48-46N/A
3/31/20247-56-53-52N/A
12/31/20238-58-52-51N/A
9/30/20238-63-56-53N/A
6/30/20238-68-60-54N/A
3/31/20239-67-51-45N/A
12/31/20229-63-49-43N/A
9/30/20227-60-47-41N/A
6/30/20227-54-37-34N/A
3/31/20225-44-36-34N/A
12/31/20214-33-18-17N/A
9/30/20212-21-8-8N/A
6/30/20211-11-4-3N/A
3/31/20210-822N/A
12/31/2020N/A-7-4-4N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: JANX förväntas förbli olönsam under de kommande 3 åren.

Resultat vs marknad: JANX förväntas förbli olönsam under de kommande 3 åren.

Höga tillväxtresultat: JANX förväntas förbli olönsam under de kommande 3 åren.

Intäkt vs marknad: JANX s intäkter ( 45.1% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).

Hög tillväxtintäkter: JANX s intäkter ( 45.1% per år) förutspås växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: JANX förväntas bli olönsam om 3 år.

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/21 09:46
Aktiekurs vid dagens slut2026/05/21 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Janux Therapeutics, Inc. bevakas av 23 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Etzer DaroutBarclays
Alec StranahanBofA Global Research
Suranjit MukherjeeBTIG